The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy

Conclusion These preliminary data point to a possible efficacy of ibrutinib in anti-MAG antibody neuropathy, which is the most common disabling paraproteinemic neuropathy, where active treatment is eagerly needed. Classification of evidence This study provides Class IV evidence that for patients with anti-MAG antibody neuropathy, ibrutinib improves neuropathy symptoms.

http://nn.neurology.org/cgi/content/short/7/4/e720?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - April 12, 2020 Category: Neurology Authors: Castellani, F., Visentin, A., Campagnolo, M., Salvalaggio, A., Cacciavillani, M., Candiotto, C., Bertorelle, R., Trentin, L., Briani, C. Tags: All Immunology, Peripheral neuropathy Article Source Type: research